Abstract
Common radionuclides used for radiometabolic therapy include 131I, 153Sm, 89Sr, 223Ra, and 90Y. In this chapter we will focus on therapeutic radiopharmaceuticals are employed for therapy of differentiated follicular thyroid carcinomas,for therapy of pheochromocytoma/paraganglioma/neuroblastomas, for bone pain palliation, for radioimmunotherapy of lymphomas, for peptide radioreceptor therapy of neuroendocrine tumors, and for intra-arterial radioembolization of hypervascularized tumors of the liver.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 153Sm-EDTMP:
-
153Sm-ethylenediamine tetramethylene phosphoric acid
- 188Re-HEDP:
-
188Re-hydro-ethylidene diphosphate
- CCK:
-
Cholecystokinin
- DIT:
-
Diiodotyrosine
- DOTA:
-
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (macrocyclic coupling agent to label compounds of biological interest with metal radionuclides)
- DOTA-TATE:
-
DOTA-D-Phe1-Tyr3-octreotate
- DOTA-TATE:
-
DOTA-Tyr3-Thre8-octreotide
- DOTA-TOC:
-
DOTA-D-Phe1-Tyr3-octreotide
- GLP-1:
-
Glucagon-like peptide-1
- GRP:
-
Gastrin-releasing peptide
- Gy:
-
Gray unit (ionizing radiation dose in the International System of Units, corresponding to the absorption of one joule of radiation energy per kilogram of matter)
- HACA:
-
Human anti-chimeric antibody
- HAHA:
-
Human anti-human antibody
- HAMA:
-
Human anti-mouse antibody
- KI:
-
Potassium iodide
- LET:
-
Linear energy transfer
- MIBG:
-
Meta-iodobenzylguanidine
- MIT:
-
Monoiodotyrosine
- NET:
-
Neuroendocrine tumor
- NHL:
-
Non-Hodgkin’s lymphoma
- NIS:
-
Sodium-iodide symporter
- PRRT:
-
Peptide receptor radionuclide therapy
- RGD:
-
Tripeptide composed of L-arginine, glycine, and L-aspartic acid
- RIT:
-
Radioimmunotherapy
- SSTR:
-
Somatostatin receptors
- T3:
-
3,5,3′-Triiodothyronine
- T4:
-
3,5,3′,5′-Tetraiodothyronine
- TSH:
-
Thyroid stimulating hormone
Suggested Readings
Baum RP, editor. Therapeutic nuclear medicine. New York: Springer; 2014.
Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F, European Association of Nuclear Medicine (EANM). EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008;35:1934–40.
Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.
Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. New York: Churchill Livingston; 2004.
Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38:1393–406.
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G, EANM. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35:1039–47.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
Herbert JC, Eckelman WC, Neumann RD, editors. Nuclear medicine – diagnosis and therapy. New York: Thieme Medical Publishers; 1996.
IAEA. Good practice for introducing radiopharmaceuticals for clinical use. Vienna: International Atomic Energy Agency (IAEA); 2015.
IAEA. Operational guidance on Hospital radiopharmacy. Vienna: International Atomic Energy Agency (IAEA); 2008.
Knapp FF, Dash A. Radiopharmaceuticals for therapy. New Delhi: Springer; 2016.
Kowalsky RJ, Falen SW, editors. Radiopharmaceuticals in nuclear pharmacy and nuclear medicine. 3rd ed. Washington, DC: American Pharmacists Association; 2011.
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, European Association of Nuclear Medicine (EANM), et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.
Owunwanne A, Patel M, Sadek S, editors. The handbook of radiopharmaceuticals. New York: Springer; 1995.
Schwochau K, editor. Technetium: chemistry and radiopharmaceuticals. Hoboken: Wiley; 2000.
Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand M, et al. The SNM practice guideline for therapy of thyroid disease with 131I 3.0*. J Nucl Med. 2012;53:1633–51.
Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37:2218–28.
Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, et al. EANM procedure guideline for radioimmunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34:616–22.
Theobald T, editor. Sampson’s texbook of radiopharmacy. 4th ed. London: Pharmaceutical Press; 2010.
Welch MJ, Redvanly CS, editors. Handbook of radiopharmaceuticals: radiochemistry and applications. Hoboken: Wiley; 2003.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this entry
Cite this entry
Orsini, F., Mazzarri, S., Puta, E., Guidoccio, F., Lorenzoni, A., Mariani, G. (2017). Radiopharmaceuticals for Therapy. In: Strauss, H., Mariani, G., Volterrani, D., Larson, S. (eds) Nuclear Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-26236-9_34
Download citation
DOI: https://doi.org/10.1007/978-3-319-26236-9_34
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26234-5
Online ISBN: 978-3-319-26236-9
eBook Packages: MedicineReference Module Medicine